Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Jun 09, 2025
- Pharmaceuticals
- R&D
Galderma’s Announcement Regarding NEMLUVIO (New Long Term Data Presentation in Atopic Dermatitis)
TOKYO, June 9, 2025 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Galderma (SIX: GALD) issued a news release regarding presentation of the results of two-year data from a new interim analysis of the ARCADIA long-term extension study of NEMLUVIO® (nemolizumab) in moderate-to-severe atopic dermatitis, at the Revolutionizing Atopic Dermatitis (RAD) Conference. NEMLUVIO is a humanized anti-human IL-31 receptor A monoclonal antibody created by Chugai. Clinical development and marketing of NEMLUVIO outside Japan is being conducted by Galderma.
Please refer to the link below for details of the Galderma’s news release:
RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years
https://www.galderma.com/news/rad-2025-nemluvio
Trademarks used or mentioned in this release are protected by laws.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Hideki Sato
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Takayuki Sakurai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp